Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer (RESCUE-GC)

  • End date
    Feb 10, 2024
  • participants needed
  • sponsor
    Beijing Cancer Hospital
Updated on 25 February 2022
cancer chemotherapy
adjuvant chemotherapy
d2 lymph node dissection


The purpose of the study is to evaluate the efficacy and safety of S-1 plus Oxaliplatin versus S-1 only as adjuvant chemotherapy after curative distal gastrectomy in patients with locally advanced gastric cancer.


The study is a multi-central, controlled, randomized Phase III trial. The protocol has been approved by the Ethics Committee of Beijing Cancer Hospital. The primary endpoint is the 3-year progression-free survival (PFS) rate. The secondary endpoints are the overall survival (OS) and safety.

Condition Gastric Cancer
Treatment Oxaliplatin plus S-1, S-1 only
Clinical Study IdentifierNCT02867839
SponsorBeijing Cancer Hospital
Last Modified on25 February 2022


Yes No Not Sure

Inclusion Criteria

sign written informed consent form
age 18 years, 69 years
ECOG status: 0~2
pathologically confirmed gastric cancer at stage II or IIIA (AJCC 7th version)
negative peritoneal cytology
underwent curative distal gastrectomy with D2 lymph node dissection
no prior antitumor treatment is allowed, including chemotherapy, radiotherapy, immune therapy or target therapy
adequate organ function as defined below: Hematologic ANC 2 _109/L, Platelets 100_ 109/L, AST and ALT 2.5ULN, TBIL 1.5ULN

Exclusion Criteria

be enrolled in other clinical trials
underwent prior antitumor treatment
allergic reaction to S-1 or oxaliplatin
abnormal GI tract function
female in pregnancy or lactation, or refuse to receive Contraception measures during chemotherapy
other situation to be judged not adaptive to the study by investigators
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note